FDA approved zilganersen as the first disease-modifying therapy for Alexander disease, an ultra-rare, progressive ...

Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...

Ultragenyx is reviewing program disposition and implementing significant expense reductions as brokerages cut price targets ...

Ionis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical ...

In a conversation with Pharmaceutical Executive, Nate Hill, Co-Founder & CEO of Strive Pharmacy, discussed the regulatory ...

Eli Lilly & Company and Merida Biosciences announced a definitive agreement for Eli Lilly to acquire Merida, to advance ...

Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer ...

The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA ...

The Trump administration adds nine midsize pharmaceutical companies, including Teva, UCB, Astellas, and BeOne Medicines to ...

President Donald Trump’s administration is preparing to announce a new round of drug-pricing agreements with midsize biotech ...

Recently, Pharmaceutical Executive spoke with Christian Thienel, director at Back Bay Life Sciences, about the ongoing issues ...

ACTO CEO Parth Khanna on why sales reps still matter — and how human intelligence plus empathetic agents is the winning formula for field teams.